Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer

BMC Cancer

Table 4 Univariate and multivariate Cox proportional hazards regression analyses of the clinicopathological parameters

	Univariate			Multivariate
	HR	95% CI	p value	HR	95% CI	p value
Age
< 50	1.00
≥ 50	2.03	0.96–4.28	0.06
Menopausal status
Premenopausal	1.00			1.00
Postmenopausal	2.15	1.07–4.34	0.03	2.27	1.07–4.78	0.03
Histological type
Invasive ductal carcinoma	1.00
Special type	0.61	0.23–1.58	0.30
Subtype
Luminal	1.00			1.00
Luminal HER2	0.20	0.04–0.88	0.03	0.19	0.04–0.82	0.03
HER2 enriched	0.92	0.31–2.70	0.89	1.01	0.32–3.15	0.97
TNBC	1.20	0.48–2.98	0.68	2.20	0.80–6.06	0.12
Pre-NAC clinical stage
Stage II	1.00			1.00
Stage III	2.18	1.10–4.32	0.02	2.43	1.18–5.00	0.02
Pathological response to NAC
Non-pCR	1.00
pCR	0.22	0.05–0.95	0.04	0.34	0.07–1.54	0.16
SMI
Maintained	1.00			1.00
Increased	0.43	0.13–1.40	0.16	0.49	0.14–1.72	0.20
Decreased	3.46	1.56–7.65	< 0.01	3.68	1.52–8.96	< 0.01
BMI
Maintained	1.00
Increased	1.61	0.67–3.86	0.28
Decreased	1.26	0.54–2.90	0.58
Alb
Increased	1.00
Decreased	1.14	0.49–2.63	0.75
NLR
Increased	1.00
Decreased	1.10	0.51–2.21	0.77

NAC Neoadjuvant chemotherapy, HER2 Human epidermal growth factor receptor type 2, pCR Pathological complete response, SMI Skeletal muscle mass index, BMI Body mass index, Alb: Serum albumin level, NLR Neutrophil-to-lymphocyte ratio

ISSN: 1471-2407